Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Moves Ahead With Adverse Event Data-Mining; “White Paper” Out Soon

Executive Summary

An FDA-PhRMA working group is finalizing a "white paper" on data mining as a tool in postmarketing safety surveillance

You may also be interested in...



PhRMA Aims To Clarify Use Of AERS Signals Through Data Mining Studies

While all sources of reports to FDA's Adverse Event Reporting System make significant contributions to signal detection, foreign sources appear to be one of the strongest contributors, preliminary results from a PhRMA-sponsored study of the database suggest

PhRMA Aims To Clarify Use Of AERS Signals Through Data Mining Studies

While all sources of reports to FDA's Adverse Event Reporting System make significant contributions to signal detection, foreign sources appear to be one of the strongest contributors, preliminary results from a PhRMA-sponsored study of the database suggest

FDA Drug Name Guidance Is “Up In The Air,” Agency Tells DIA

FDA may not proceed with a planned guidance for industry on pre-marketing risk assessment of drug names, labeling and packaging, Medical Errors & Technical Support Division Deputy Director Carol Holquist said at the Drug Information Association annual meeting in Washington, D.C. June 16

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS043206

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel